Illumina, Inc. (ILMN) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 62,800 shares of the life sciences company’s stock after selling 700 shares during the period. Point72 Asset Management L.P.’s holdings in Illumina were worth $12,510,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Dupont Capital Management Corp acquired a new position in Illumina during the third quarter worth $153,000. Advisory Services Network LLC raised its position in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares during the period. Penserra Capital Management LLC raised its position in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after acquiring an additional 102 shares during the period. Paradigm Asset Management Co. LLC raised its position in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after acquiring an additional 50 shares during the period. Finally, West Coast Financial LLC acquired a new position in Illumina during the third quarter worth $216,000. Institutional investors own 91.75% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at $216.55 on Friday. Illumina, Inc. has a 12-month low of $126.18 and a 12-month high of $230.72. The company has a market cap of $30,784.10, a PE ratio of 61.65, a PEG ratio of 3.48 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the business earned $0.97 earnings per share. Illumina’s revenue was up 17.6% compared to the same quarter last year. sell-side analysts anticipate that Illumina, Inc. will post 3.75 EPS for the current fiscal year.

A number of equities analysts have weighed in on ILMN shares. Barclays upped their price objective on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price objective for the company in a research report on Friday, October 27th. Canaccord Genuity restated a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Piper Jaffray Companies restated an “overweight” rating and set a $226.00 price objective (up from $202.00) on shares of Illumina in a research report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded shares of Illumina from a “sell” rating to a “neutral” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $202.60.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $200.16, for a total transaction of $4,003,200.00. Following the completion of the transaction, the director now owns 539,176 shares of the company’s stock, valued at $107,921,468.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total transaction of $29,323.35. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,421 shares of company stock valued at $28,489,101. 0.89% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) Shares Sold by Point72 Asset Management L.P.” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/16/illumina-inc-ilmn-shares-sold-by-point72-asset-management-l-p.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit